Watching a retail roadshow presentation of an interesting company with a different approach (then I am familiar with at least). Their lead program is for recurrent C Diff, SER-109. They have a breakthrough designation already for those who care about those things. The CEO sounds a bit overly confident (maybe that is good though). What makes them unusual (to me) is their approach From their website
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.